Albumin for acute variceal bleeding in cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This trial tests if giving albumin, a protein in the blood, can improve outcomes for patients with cirrhosis who have a specific type of bleeding from enlarged veins in the esophagus or stomach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult between 18 and 70 years old.
- You must have cirrhosis (liver scarring) and be experiencing active bleeding from varices (enlarged veins in the esophagus or stomach).
- You cannot have been treated with albumin in the last month.
- You cannot have certain other liver or blood vessel conditions like portal vein thrombosis or liver cancer.
- You cannot have heart failure, chronic kidney disease, or conditions that cause fluid overload.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving albumin (a protein) along with water pills helps reduce leg swelling in people with cirrhosis and ascites. It may be an option if your leg swelling hasn't improved with standard diuretics alone.
This trial tests if giving tranexamic acid and vitamin K by injection can help control bleeding from the upper digestive tract in people with liver cirrhosis. It may offer a way to stop bleeding more quickly.
This trial tests whether giving albumin (a blood protein) in a personalized dose works better than a standard fixed dose for people with cirrhosis and sepsis-related acute kidney injury. The goal is to find a safer and more effective way to protect kidney function.
This Phase 2 trial tests whether giving albumin together with enoxaparin (a blood thinner) can improve outcomes for people hospitalized with decompensated cirrhosis who are at high risk. It may help your recovery after certain serious liver-related complications and reduce the chance of poor outcomes.
This trial tests whether a personalized long-term albumin (a blood protein medicine) can help people with advanced liver scarring who have fluid in the belly (ascites). It compares the personalized albumin approach to standard care to see if it improves outcomes over time.
This study looks at a simple blood test score called the Albumin-Bilirubin (ALBI) index to see how well it predicts recovery in people with bleeding from enlarged veins in the esophagus (varices). It may help doctors better understand your risk and guide treatment.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.